THANK YOU FOR SUBSCRIBING
× 
Startup City Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Startup City
Startup City
Kristofer Cook, CEO
“We see a clear interest in more accurate gut microbiome data as a means to personalize interventions. Our low-cost test allows for longitudinal data collection overcoming the natural variability of gut health data,” says Kristofer Cook, CEO at Carbiotix. Gut health can only be measured over time with multiple gut bacteria samples. Poor gut health stems from little consumption of soluble fibers, and it requires time to both improve gut health and to diagnose its deterioration.
Our competitive advantage is derived from our low-cost gut health testing services, which serves to accelerate therapeutics development
Carbiotix’s key differentiator derives from a superior second-generation soluble fiber (AXOS), isolated strains from real life studies, and novel delivery mechanisms that allow them to optimize an individual’s microbiome metabolic profile. Furthermore, the company’s platform-based microbiome therapeutics technology offering is able to address a range of metabolic and chronic diseases. Their primary focus will be on bringing rare disease therapeutics to market while partnering with leading drug companies to develop treatments and medications for the same. They are already en-route to developing therapies for hyperammonemia and chronic kidney diseases (in the proof of concept stage) and, IBD, type-II diabetes, and osteoarthritis (in the pre-clinical stage). “We have collected 18 months of longitudinal data, with over 2,000 samples analyzed to date. Among our users, we have had people who have dramatically improved their baseline gut health with increased consumption of high-quality soluble fiber,” adds Cook. In the light of this promising observation, Cook also plans to roll out their fibers in the form of readily consumable nutritional products for the consumer masses.
Evidently, the trio of initiatives namely, the gut testing service, the clinical development partnership, and the nutritional supplement can mutually aid each other. “Our competitive advantage is derived from our low-cost gut health testing services sold to consumers and businesses, which serves to accelerate therapeutics development, potentially diagnose diseases, and verify and amplify the efficacy of our therapeutics,” mentions Cook.
Being an award-winning spin-off company from the department of biotechnology at Lund University, Carbiotix is all set to bring out B2B offerings later this year. It is Cook’s fourth biotech startup; evidently, he is well positioned and experienced to lead it forward. “We try and take this to a new level by respecting human evolution and restoring people’s gut microbiomes to a state where we not only can treat diseases but also prevent the development of diseases in the first place, of course, verified with our low-cost test,” concludes Cook.
Carbiotix News
Carbiotix’s CEO and chairman buys shares in Carbiotix
Carbiotix CEO Erik Deaner acquired a total of 138,220 shares on October 4, 2023, at an average price of 0,71 kronor per share. Before this acquisition, Erik Deaner's total ownership amounted to 44,612 shares, corresponding to approximately 0.22 percent. After the acquisition, the holding amounts to 182,832 shares, corresponding to approximately 0.88 percent of the votes and capital in the Company.
On October 5, the Company's chairman, Kristofer Cook, also purchased a total of 124,361 shares at an average price of 0,7 kronor per share through his holding company Sustainable Holding Sweden AB. Before this acquisition, Kristofer Cook's total holdings amounted to 3,875,639 shares, corresponding to 18.69 percent. After the acquisition, the holding amounts to 4,000,000 shares, corresponding to approximately 19.28 percent of the votes and capital in the Company.
All transactions were carried out in ongoing trading.
Erik Deaner, CEO of Carbiotix, comments
"I have chosen to increase my holdings in Carbiotix because I strongly believe in the Company's future. My confidence is based on the growing interest in LinkGut, our gut health testing service, and the commercialization of our first CarbiAXOS product. I have great faith in our dedicated team, which is why I have chosen to quadruple my previous holdings.”
Forward-looking statements
This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios as described in this press release.